BBOT — Bridgebio Oncology Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapMomentum Trap

Annual income statement for Bridgebio Oncology Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	10-K
Standards:	USG	USG	USG	USG
Status:	Final	Final	Final	Final
Total Revenue	0	0	0	0
Selling / General / Administrative Expenses
Other Operating Expenses
Total Operating Expenses	0.043	0.004	0.042	0.584
Operating Profit	-0.043	-0.004	-0.042	-0.584
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.043	-0.004	-0.042	7.6
Net Income After Taxes	-0.043	-0.004	-0.042	7.6
Net Income Before Extraordinary Items
Net Income	-0.043	-0.004	-0.042	7.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-0.043	-0.004	-0.042	7.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.002	-0	-0.002	0.358
Dividends per Share